In the early phases of the COVID-19 pandemic, amid shortages for essential medicines, reagents, and equipment, the European Commission (EC) struggled to develop a coordinated and comprehensive European response [1,2]. The EC now seeks to strengthen its role in preparedness planning and response through, among other measures, the establishment of the European Union (EU) Health Emergency Preparedness and Response Authority (HERA) [3]. While the remit and scope of HERA is yet to be formally agreed, it is envisaged to play a similar role to the US Biomedical Advanced Research and Development Authority (BARDA) and be responsible for:[4]
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: